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Abstract
Aims/hypothesis—We aimed to determine the persistence of glycaemic control 1 year after a 
limited period of intensive glycaemic management of type 2 diabetes.
Methods—4119 ACCORD Trial participants randomized to target HbA1c <6.0% (42 mmol/mol) 
for 4.0±1.2 years were systematically transitioned to target HbA1c 7.0–7.9% (53–63 mmol/mol) 
and followed for an additional 1.1±0.2 years. Characteristics of participants with HbA1c <6.5% 
(48 mmol/mol) or ≥6.5% at transition were compared. Changes in BMI and glucose-lowering 
medications were compared between those ending with HbA1c <6.5% vs ≥6.5%. Poisson models 
were used to assess the independent effect of attaining HbA1c <6.5% before transition on ending 
with HbA1c <6.5%.
Results—Participants with pre-transition HbA1c <6.5% were older with shorter duration diabetes 
and took less insulin but more non-insulin glucose-lowering agents than those with higher HbA1c. 
A total of 823 participants achieved a final HbA1c <6.5%, and had greater post-transition 
reductions in BMI, insulin dose and secretagogue and acarbose use than those with higher HbA1c 
(p<0.0001). HbA1c <6.5% at transition predicted final HbA1c <6.5% (crude RR 4.9 [95% CI 4.0, 
5.9]; RR 3.9 [95% CI 3.2, 4.8] adjusted for demographics, co-interventions, pre-intervention 
HbA1c, BMI and glucose-lowering medication, and post-transition change in both BMI and 
glucose-lowering medication). Progressively lower pre-transition HbA1c levels were associated 
with a greater likelihood of maintaining a final HbA1c of <6.5%. Follow-up duration was not 
associated with post-transition rise in HbA1c.
Conclusions/interpretation—Time-limited intensive glycaemic management using a 
combination of agents that achieves HbA1c levels below 6.5% in established diabetes is associated 
with glycaemic control more than 1 year after therapy is relaxed.
Keywords
Intensive glucose lowering; Long-term glycaemic control; Post-intervention follow-up; Type 2 
diabetes
Introduction
Type 2 diabetes is generally regarded as a slowly progressive disease characterised by a 
reduction in ability to maintain glucose homeostasis over time [1] and a concomitant 
increase in the need for pharmacological therapy to do so. Recent observations that bariatric 
surgery seems to slow or even reverse this process [2, 3] suggest that diabetes is not 
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necessarily progressive and that beta cell function and the capacity to make insulin can be 
improved [4, 5] in association with reduced body mass and food intake. Additional evidence 
suggests that short-term intensive insulin therapy early in the course of diabetes [6] plus 
lifestyle modification [7] may have persistent effects on glycaemic control by reducing the 
demand on the beta cells to secrete insulin, thereby preserving their function [8, 9], or by 
improving adherence to health-promoting behaviours. Other agents, including 
thiazolidinediones and incretin mimetics, also improve beta cell function [8, 9]. It is not 
known whether a strategy of prolonged multimodal intensive glucose lowering has durable 
effects.
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial (NCT00000620) 
was designed to study the cardiovascular effects of intensive glycaemic control, intensive 
blood pressure control, and fibrate use among people with type 2 diabetes. As previously 
reported [10], the intensive glycaemic intervention was discontinued after the independent 
data and safety monitoring board noted excess mortality in that group. As a result, 
participants who had been randomised to intensive glycaemic management (i.e. targeting an 
HbA1c of <6.0% [42 mmol/mol]) and who, as a group, had reduced their entry median 
HbA1c from 8.1% (65 mmol/mol) to 6.4% (46 mmol/mol) were all transitioned to the 
standard glycaemic management strategy (i.e. targeting an HbA1c of 7.0–7.9% [53–63 
mmol/mol]), and continued to be followed until the blood pressure and lipid trials that were 
part of the initial ACCORD design were completed about 1 year later. By the end of the 
follow-up period, the HbA1c in this group was 7.4±1.2% compared with 7.8±1.2% in the 
group randomised to standard care [11]. This situation offered a unique opportunity to 
observe the glycaemic effects of intentional relaxation of glycaemic therapy in a group of 
patients who started out with poorly controlled (HbA1c >7.5% [58 mmol/mol]), 
longstanding (median 10 years) type 2 diabetes, and who achieved near-normal HbA1c 
levels during more than 3 years of intensive glucose lowering. This report therefore 
describes the metabolic course of participants randomised to the intensive glycaemia group 
who had at least one visit before transition and one visit after transition to a standard 
glycaemic management approach, and determines whether a period of intensive glucose 
lowering that achieved normal or near-normal glucose levels is associated with persistence 
of glycaemic control after relaxation of therapy.
Methods
ACCORD Trial
The design of the ACCORD Trial has been described previously [12, 13]. Briefly, 10,251 
participants aged 40–79 years with type 2 diabetes, an HbA1c ≥7.5% and additional 
cardiovascular risk factors were recruited at 77 sites in North America. Participants were 
randomised to either intensive glycaemic management targeting an HbA1c of <6.0% or 
standard glycaemic management targeting an HbA1c of 7.0–7.9%. In a double 2×2 factorial 
design, 4,733 participants were also randomised to either intensive blood pressure lowering 
(<120/80 mmHg) or standard blood pressure lowering (130–139/80–90 mmHg), and the 
remaining 5,518 participants were randomised to the addition of fenofibrate or placebo to 
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statin therapy. The trial was approved by ethics committees at all participating sites, and all 
participants gave informed consent.
The intensive glycaemic management strategy targeting an HbA1c of <6.0% involved 
monthly visits for the first 4 months followed by visits every 1–2 months, which included 
review of logs of self-monitoring of blood glucose (SMBG; performed two to eight times 
per day) and point-of-care HbA1c (every 2 months), review and prescription or titration of 
glucose-lowering medication from all approved classes in any combination to further lower 
HbA1c if it could be achieved safely while avoiding hypoglycaemia, and education 
regarding diabetes self-management including diet, physical activity, insulin self-titration, 
hypoglycaemia avoidance and management, with additional supportive phone calls between 
visits.
The standard management strategy targeting an HbA1c of 7.0–7.9% included visits every 4 
months (except for participants also randomised to intensive blood pressure control, who 
had visits every 2 months) to review logs of SMBG (performed a few times per week to 
three times per day), education regarding diabetes self-management as needed, and review 
and prescription or titration of glucose-lowering medication including down-titration for any 
of the following reasons: severe or frequent symptomatic hypoglycaemia; 50% or more 
SMBG values below 5 mmol/l (90 mg/dl); or in the setting of either one HbA1c <6.5% or 
consecutive HbA1c values <7.0%, any of use of insulin or a secretagogue, any symptomatic 
hypoglycaemia or any SMBG below 5 mmol/l (90 mg/dl).
An extra visit was scheduled for all intensive group participants at the time of the transition 
to explain the new HbA1c goal of 7.0–7.9%, and their conversion to the standard 
management strategy of the trial as described above. At this transition visit, research staff 
reviewed SMBG values, point-of-care HbA1c and medications, and down-titrated 
medications for individuals with an HbA1c <7.0%.
Glucose-lowering medications, BMI and a centrally measured HbA1c were documented 
prior to randomisation and at least every 4 months for all participants throughout the study. 
Glycaemic status of all participants was reviewed centrally and reported to investigators 
regularly to promote adherence to the standard glycaemic management strategy after 
transition. In particular, site investigators were sent regular reminders of the down-titration 
algorithm, reports indicating the proportion of formerly intensive group participants at their 
site whose medications were down-titrated according to the standard management algorithm, 
and listings of intensive group participants whose HbA1c remained <7.0%. Extra visits or 
phone calls were completed to further down-titrate glucose-lowering medications as needed 
to achieve an HbA1c of 7.0–7.9%.
The last study visit on or before the date of the transition at which HbA1c was measured 
centrally was considered the pre-transition visit, and pre-transition values were obtained 
from that visit. Thereafter, the last study visit at which HbA1c was measured centrally was 
considered the final post-transition visit, and post-transition values were obtained from that 
visit.
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All participants allocated to the intensive group who were alive at the time of transition and 
who had at least one HbA1c measurement at or before the date of transition and at least one 
measurement after the transition date were included in this analysis.
Statistical methods
All analyses were conducted using SAS software version 9.1 (SAS Institute, Cary, NC, 
USA). Two-sided p values <0.05 were considered nominally significant. Before any 
analyses were conducted, a decision was made to assess the effect of achieving a pre-
transition HbA1c <6.5% on the final HbA1c level. This threshold was chosen because it was 
just above the median HbA1c level achieved in the intensive group during the ACCORD 
Trial (i.e. 6.4%) and thus represented approximately half of the intensive group participants. 
It is also the threshold used to diagnose diabetes [14].
Characteristics of intensive group participants whose last pre-transition HbA1c was <6.5% 
vs ≥6.5% were compared by t tests or χ2 tests. Mean insulin doses were calculated based on 
all participants; those not on insulin were assigned a dose of 0 units for the analyses. 
Participants whose final post-transition HbA1c was <6.5% vs ≥6.5% were compared for 
mean final HbA1c, post-transition change in BMI (three categories), change in insulin dose 
(three categories), and change in use of other glucose-lowering medications (added, 
continued, never prescribed or discontinued for each medication class) by χ2 tests.
RRs with 95% CI of achieving a final post-transition HbA1c <6.5% were calculated for a 
pre-transition HbA1c <6.5% vs ≥6.5% using Poisson regression, both before and after 
adjustment for baseline pre-randomisation HbA1c and demographic, anthropometric, co-
interventional and pharmacological covariates listed in Tables 1 and 2. To assess the 
relationship between the pre-transition and final HbA1c levels, RRs were calculated for 0.1% 
increments of the pre-transition HbA1c level. Comparisons were relative to those who had a 
pre-transition HbA1c equal to 6.5% using unadjusted and adjusted Poisson regression. Lines 
were fitted assuming a single linear term for pre-transition HbA1c in a log-linear model. 
Finally, to determine if HbA1c levels ‘drifted’ up with a greater duration of exposure to the 
standard glycaemic intervention after transition, a second degree penalised B-spline was 
fitted for change in HbA1c vs time between pre-transition and final HbA1c measurements 
[15].
Results
A total of 4,119 participants who were allocated to intensive glycaemic management and 
who had at least one HbA1c level measured before and after transition to the approach used 
in the standard glycaemic group were analysed. Excluded intensive group participant 
characteristics are summarised in the electronic supplementary material (ESM) Table 1 for 
comparison. The mean ± SD duration of intensive glycaemic management in the pre-
transition period was 4.0±1.2 years (range 2.3–7.0). As noted in Table 1, compared with the 
1,786 intensive group participants whose HbA1c before transition was ≥6.5%, the 2,333 who 
achieved an HbA1c before transition of <6.5% were more likely to be male, older and have 
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shorter-duration diabetes, and have access to a certified diabetes educator (CDE) at their 
investigative site at baseline. Prior to initiating intensive therapy at the time of 
randomisation, this group also had lower HbA1c levels and less use of insulin, but greater 
use of sulfonylureas and a higher BMI. At the pre-transition visit, they continued to require 
less insulin, but were more likely to be taking other glucose-lowering medications, including 
metformin, thiazolidinediones and secretagogues, than those who did not achieve an HbA1c 
<6.5% during intensive management.
These 4,119 participants were followed for a mean ± SD of 1.1±0.2 years (range 0.4–1.4) 
after their glycaemic management approach was relaxed to the standard glycaemic 
approach. At the time of the final visit, 711 participants continued to have an HbA1c <6.5%, 
1,622 had a rise from <6.5% to ≥6.5%, 112 participants had a fall from ≥6.5% to <6.5%, and 
1,674 maintained an HbA1c ≥6.5%. Among the 823 participants with a final HbA1c <6.5%, 
mean HbA1c was 6.0±0.3% (42±3 mmol/mol), and among those with a final HbA1c≥6.5%, 
the mean was 7.7±1.1% (61± 12 mmol/mol). More participants whose final HbA1c was 
<6.5% had lost weight and reduced their dose of insulin and use of secretagogues and 
acarbose from the pre-transition visit to the final post-transition visit compared with those 
who did not achieve a final HbA1c of <6.5% (Table 2).
Achieving a pre-transition HbA1c <6.5% was a strong predictor of maintaining a final 
HbA1c <6.5% (crude RR 4.9 [95% CI 4.0, 5.9], p<0.0001) (Fig. 1). This strong association 
was maintained even after adjustment for age, sex, diabetes duration, availability of a CDE 
at the study site, allocation to intensive blood pressure control, allocation to receive fibrate, 
pre-randomisation HbA1c, BMI and glucose-lowering medication use, and pre-transition 
BMI and glucose-lowering medication use (RR 4.0 [95% CI 3.3, 5.0], p<0.0001). 
Adjustment for change in both BMI and glucose-lowering medication use during the post-
transition follow-up also did not alter this association (RR 3.9 [95% CI 3.2, 4.8], p<0.0001). 
Duration of intensive management was not a significant determinant of final HbA1c (RR 
1.05 per year [95% CI 0.99, 1.12], p=0.08).
Figure 2 shows that there was no clear threshold for the effect of progressively lower pre-
transition HbA1c on the likelihood of achieving an HbA1c <6.5% after relaxation of 
glycaemic management. Indeed, there was a graded relationship such that those with lower 
pre-transition HbA1c were more likely to maintain an HbA1c <6.5% over time. Compared 
with those with a pre-transition HbA1c equal to 6.5%, those with a pre-transition HbA1c of 
6.0% or ≤5.5% (37 mmol/mol) were, respectively, 2.2 times [95% CI 1.4, 3.5] or 4.2 times 
[95% CI 2.8, 6.5] more likely to have an HbA1c <6.5% at the end of follow-up. Adjustment 
for age, sex, known diabetes duration, availability of a CDE at the study site, allocation to 
intensive blood pressure control, allocation to receive fibrate, pre-randomisation HbA1c, 
BMI and glucose-lowering medication use, and change in both BMI and glucose-lowering 
medication use during the post-transition follow-up minimally affected these estimates (2.0 
[95% CI 1.3, 3.2] and 3.7 [95% CI 2.4, 5.7], respectively).
As noted in Fig. 3, there was no relationship between change in HbA1c from pre-transition 
to the final measurement and the time interval between those two measurements.
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Achievement of tight glycaemic control for a mean of 4 years was associated with persistent 
glycaemic control thereafter. This group of people with a median self-reported duration of 
diabetes of 10 years had an HbA1c >7.5% at baseline, and were intensively managed to a 
mean of 6.5% at the time of transition. One-fifth of them had an HbA1c <6.5% after a mean 
of 1.1 years of relaxation from the intensive glycaemic therapy to a standard glycaemic 
management approach. Those who achieved an HbA1c <6.5% during intensive therapy were 
four times more likely to have a final post-transition HbA1c below 6.5% compared with 
those who were not able to achieve such tight control on intensive therapy. This analysis 
indicates that, in some patients who have established and initially suboptimally controlled 
type 2 diabetes, achieving tight glycaemic control with intensive diabetes management is 
associated with improved maintenance of subsequent glycaemic control despite transition to 
standard therapy.
There are several potential explanations for the findings, and more than one may have 
contributed to the observed outcome. First, those who achieved and maintained better 
glycaemic control may have had physiologically ‘milder’ diabetes with more beta cell 
reserve or less insulin resistance at entry into the trial. The group with pre-transition HbA1c 
<6.5% did have shorter known duration of diabetes, and, before initiating intensive 
management, they had lower HbA1c levels with less insulin use, but more sulfonylurea use 
and their BMI was higher. Nevertheless, even after adjustment for pre-randomisation and 
pre-transition characteristics, there was a strong effect of pre-transition HbA1c on post-
transition HbA1c. Second, despite the fact that the standard glycaemia approach was used to 
manage intensive group participants after transition, participants may have continued some 
unmeasured behaviours and therapies that they were using before transition. It is notable that 
participants who achieved a final HbA1c <6.5% did so despite greater down-titration of 
glucose-lowering medications than those who did not achieve a final HbA1c <6.5%. These 
lifestyle changes and decrease in medication use may have led to more weight loss after 
transition which reduced insulin resistance, allowing their endogenous insulin to be more 
effective.
Another possibility is that the period of intensive glycaemic control with multiple agents 
which resulted in near-normal glycaemia may have ‘rested’ the beta cells and allowed a 
sustained recovery of beta cell function and/or mass leading to improved glucose 
homeostasis. Indeed very early in the course of type 2 diabetes, there is supportive evidence 
for restoration of glucose homeostasis to the point of remission of diabetes for up to 2 years 
after 2–6 weeks of intensive management using insulin [6] or oral agents (gliclazide and 
metformin) [16]. In more longstanding diabetes, short-term continuous subcutaneous insulin 
infusion [17] and intensive lifestyle intervention [7] have had significant but modest effects. 
Furthermore, trials in people with impaired fasting glucose and/or impaired glucose 
tolerance have shown that diabetes can be prevented and/or normal glucose tolerance 
restored after several years of treatment with therapies that reduce the need to secrete insulin 
including lifestyle intervention, metformin [18, 19], thiazolidinediones [20, 21], acarbose 
[22] and insulin [23]. In the present study, this paradigm of therapeutic near-normalisation 
of glucose is extended to a population with longstanding diabetes using an intensive 
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combination therapy approach. Moreover, this study shows that the nearer to normal that 
glycated haemoglobin can be brought initially, the more likely sustained maintenance of 
glucose homeostasis is to be, and this is not simply because it takes longer for HbA1c to drift 
up from lower levels.
The role of each of the medications used cannot be established in this study. Greater use of 
metformin, thiazolidinediones and secretagogues was associated with better pre-transition 
glycaemic control. However, in multivari-able regression models, none of the medications 
or changes in medication was favourably associated with lower post-transition HbA1c (data 
not shown). Furthermore, adjustment for medications or changes therein did not affect the 
relationship between pre-transition and post-transition HbA1c, suggesting the types of 
medications used may be less important than the glycaemic target.
This post hoc analysis was not part of the ACCORD protocol, and must be interpreted with 
caution. However, the observation is consistent with the existing literature [2–7]. Additional 
limitations include the absence of a comparison group that did not relax glycaemic 
management. Nonetheless, both the intensive phase and the relaxation to a standard 
approach were conducted according to a structured protocol, and information about 
important covariates was systematically collected for all the 4,119 participants over the full 
intensive intervention period and the relatively long post-transition follow-up to allow 
adjustment for potential confounders. Finally, the postulated protection of beta cell function 
cannot be directly confirmed because of lack of physiological measurements in the 
ACCORD population.
Questions remain about the optimal duration and type of therapy, and the best candidate 
patients for this approach, especially in light of the ACCORD Trial finding of increased 
mortality in the intensive management group [10]. Of note, however, the subgroup of 
intensively treated participants that benefited here (those who achieve an HbA1c <6.5%) did 
not have an increased risk of mortality in the ACCORD Trial [24]. The potential benefits 
and harms of maintaining an HbA1c <6.5% despite relaxing therapy to target a higher HbA1c 
are unknown.
In summary, the results show that attainment of HbA1c levels below the diabetes threshold 
level of 6.5% during a mean 4 year period of intensive glycaemic control using a 
combination of agents is associated with subsequent durable glycaemic control. The relative 
contributions from physiological vs behavioural changes remain unknown, but the main 
observation is consistent with other lines of evidence suggesting that the progressive 
deterioration in glucose homeostasis is not necessarily irreversible in people with established 
type 2 diabetes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Effect of having an HbA1c <6.5% (48 mmol/mol) after 4.0 years of intensive diabetes 
management on the likelihood of having an HbA1c <6.5% 1.1 years after relaxation of 
glycaemic management. Demographics=sex, age and diabetes duration; Co-
interventions=CDE availability at study site, randomisation to fibrate and randomisation to 
intensive blood pressure control; Pre-Rand=at ACCORD baseline pre-randomisation; Pre-
T=last pre-transition; Post-T=post-transition; Pre-T medications=insulin dose (U kg−1 
day−1) and use of thiazolidinedione, metformin, secretagogue, acarbose and incretin mimetic 
before transition; Post-T change in BMI=category of BMI change (as in Table 2); Post-T 
change in medications=category of change in insulin dose (as in Table 2) and in use of 
thiazolidinedione, metformin, secretagogue, acarbose and incretin mimetic from before 
transition to study completion (added, continued, never prescribed, discontinued)
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Prolonged effect of the achieved HbA1c with intensive glycaemic therapy on the likelihood 
of achieving a final HbA1c <6.5%. Models are unadjusted (blue circles) and adjusted (for 
demographics, co-interventions, baseline pre-randomisation HbA1c, BMI and medications, 
and post-transition change in BMI and medications) (red circles). The y-axis displays risks 
relative to a pre-transition HbA1c of 6.5%. The lines represent a log-linear model assuming a 
single linear term for pre-transition HbA1c. To convert values for HbA1c in % into mmol/
mol, subtract 2.15 and multiply by 10.929
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Effect of time since transition to a standard glycaemic approach on the change in HbA1c 
since transition. To convert increments for HbA1c in % into mmol/mol, multiply by 10.929
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Table 1
Baseline and pre-transition characteristics of intensive group participants who were 
transitioned to standard care and followed-up after transition
Characteristic Last HbA1c before transition <6.5% 
(n=2,333a)
Last HbA1c before transition ≥6.5% (n 
=1,786a)
p value
Female 843 (36.1) 732 (41.0) 0.002
Randomised to receive fibrate 628 (26.9) 475 (26.6) 0.8
Randomised to intensive BP control 511 (21.9) 410 (23.0) 0.4
CDE availability at site 976 (41.8) 662 (37.1) 0.002
At randomisation
 HbA1c (%) 8.1±1.0 8.5±1.0 <0.0001
 HbA1c (mmol/mol) 65±11 69±11 <0.0001
 BMI (kg/m2) 32.4±5.4 32.0±5.5 0.009
 Insulin use 600 (25.7) 791 (44.3) <0.0001
 Metformin use 1,407 (60.3) 1,099 (61.5) 0.4
 Thiazolidinedione use 444 (19.0) 372 (20.8) 0.2
 Sulfonylurea use 1,257 (53.9) 861 (48.2) 0.0003
 Meglitinide use 47 (2.0) 37 (2.1) 0.9
 α-Glucosidase inhibitor use 9 (0.4) 20 (1.1) 0.005
At transition
 Age (years) 66.1±6.6 65.3±7.0 <0.0001
 Diabetes duration (years) 13.5±7.6 15.8±8.0 <0.0001
 HbA1c (%) 5.9±0.3 7.3±0.9 <0.0001
 HbA1c (mmol/mol) 41 ±3 56±10 <0.0001
 BMI (kg/m2) 33.3±6.1 33.6±6.2 0.1
 Total daily insulin dose (U/kg)b 0.4±0.4 0.7±0.6 <0.0001
 Metformin use 1,900 (81.4) 1,324 (74.1) <0.0001
 Thiazolidinedione use 1,489 (63.8) 846 (47.4) <0.0001
 Secretagogue use 1,541 (66.1) 1,043 (58.4) <0.0001
 Acarbose use 333 (14.3) 290 (16.2) 0.08
 Incretin mimetic use 355 (15.2) 270 (15.1) 0.9
Values are expressed as n (%) or mean ± SD
a
Includes those with at least one visit after transition
b
Includes those taking 0 U
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Table 2
Changes in BMI and medication use from the last pre-transition visit to study completion
Characteristic Change from pre-transition to final Final achieved HbA1c <6.5% 
(n=823)
Final achieved HbA1c ≥6.5% 
(n=3,296)
p value
BMI ≥3% increase 115 (14.0) 570 (17.3)
Between −3% and +3% 379 (46.1) 1,697 (51.5) <0.0001
≥3% decrease 329 (40.0) 1,029 (31.2)
Insulin dose ≥15% increasea 51 (6.2) 624 (18.9)
Between −15% and +15%b 464 (56.4) 1,681 (51.0) <0.0001
≥15% decreasec 308 (37.4) 991 (30.1)
Metformin Added/continued 585 (71.1) 2,423 (73.5) 0.2
Never prescribed/discontinued 238 (28.9) 873 (26.5)
Thiazolidinedione Added/continued 211 (25.6) 888 (26.9) 0.4
Never prescribed/discontinued 612 (74.4) 24.8 (73.1)
Secretagogue Added/continued 334 (40.6) 1,623 (49.2) <0.0001
Never prescribed/discontinued 489 (59.4) 1,673 (50.8)
Acarbose Added/continued 28 (3.4) 233 (7.1) 0.0001
Never prescribed/discontinued 795 (96.6) 3,063 (92.9)
Incretin mimetic Added/continued 59 (7.2) 271 (8.2) 0.3
Never prescribed/discontinued 764 (92.8) 3,016 (91.8)
Values are expressed as n (%)
a
Includes those who started insulin after transition
b
Includes those who were not prescribed insulin at any point before or after transition
c
Includes those who discontinued insulin at or after transition
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